These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 37477145)

  • 1. HER3/Akt/mTOR pathway is a key therapeutic target for the reduction of triple‑negative breast cancer metastasis via the inhibition of CXCR4 expression.
    Takeda T; Tsubaki M; Genno S; Tokunaga K; Tanaka R; Nishida S
    Int J Mol Med; 2023 Sep; 52(3):. PubMed ID: 37477145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.
    Chen G; Chen SM; Wang X; Ding XF; Ding J; Meng LH
    J Biol Chem; 2012 Apr; 287(15):12132-41. PubMed ID: 22337890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
    Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
    Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of miR‑214 attenuates the migration and invasion of triple‑negative breast cancer cells.
    Zhang Y; Zhao Z; Li S; Dong L; Li Y; Mao Y; Liang Y; Tao Y; Ma J
    Mol Med Rep; 2019 May; 19(5):4035-4042. PubMed ID: 30942417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
    Wu C; Qiu S; Liu P; Ge Y; Gao X
    J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silence of α1-Antitrypsin Inhibits Migration and Proliferation of Triple Negative Breast Cancer Cells.
    Zhao Z; Ma J; Mao Y; Dong L; Li S; Zhang Y
    Med Sci Monit; 2018 Sep; 24():6851-6860. PubMed ID: 30260937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer.
    Li G; Hu J; Cho C; Cui J; Li A; Ren P; Zhou J; Wei W; Zhang T; Liu X; Liu W
    Cell Signal; 2023 Sep; 109():110729. PubMed ID: 37257766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
    Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
    Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer.
    Wen W; Marcinkowski E; Luyimbazi D; Luu T; Xing Q; Yan J; Wang Y; Wu J; Guo Y; Tully D; Han ES; Yost SE; Yuan Y; Yim JH
    Cells; 2019 Aug; 8(9):. PubMed ID: 31480338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
    Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
    Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
    Hatem R; El Botty R; Chateau-Joubert S; Servely JL; Labiod D; de Plater L; Assayag F; Coussy F; Callens C; Vacher S; Reyal F; Cosulich S; Diéras V; Bièche I; Marangoni E
    Oncotarget; 2016 Jul; 7(30):48206-48219. PubMed ID: 27374081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ROR2 promotes invasion and chemoresistance of triple-negative breast cancer cells by activating PI3K/AKT/mTOR signaling.
    DA X; Ge H; Shi J; Zhu C; Wang G; Fang Y; Xu J
    Oncol Res; 2024; 32(7):1209-1219. PubMed ID: 38948021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Costa RLB; Han HS; Gradishar WJ
    Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer.
    Huang MY; Hu SY; Dong J; Deng L; Andriani L; Ma XY; Zhang YL; Zhang FL; Shao ZM; Li DQ
    Cancer Res; 2024 Aug; 84(16):2660-2673. PubMed ID: 38748783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GBP2 enhances paclitaxel sensitivity in triple‑negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the PI3K/AKT/mTOR pathway.
    Zhang W; Tang X; Peng Y; Xu Y; Liu L; Liu S
    Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38334171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.
    Du L; Li X; Zhen L; Chen W; Mu L; Zhang Y; Song A
    Mol Med Rep; 2018 May; 17(5):7163-7169. PubMed ID: 29568883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.
    El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
    Sci Rep; 2020 Apr; 10(1):6367. PubMed ID: 32286420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of REG3A promotes tumorigenic behavior in triple negative breast cancer cells.
    Jin X; Yang S; Lu X; Chen X; Dai W
    Breast Cancer Res; 2024 Jun; 26(1):92. PubMed ID: 38840145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
    Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
    Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.